MBX Biosciences (MBX) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $50.71, +3.87% vs the prior close of $48.82.
- Volume 601.80K shares, 1.2x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
MBX jumps 3.9% to $50.71. Closed at $50.71, +3.87% vs the prior close of $48.82. Day range $48.73–$51.30, opened at $49.15.
MBX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — MBX jumps 3.9% to $50.71
- Closed at $50.71, +3.87% vs the prior close of $48.82. Day range $48.73–$51.30, opened at $49.15.
- Volume was 601.80K shares, 1.2x its 50-day average of 500.25K.
- Price is -17.0% vs its 50-day average ($61.08) and +13.9% vs its 200-day average ($44.51).
- 52-week range $12.94–$72.64; today's close sits at 63% of that range, 30.2% below the 52-week high.
Oct 14, 2026 — MBX dips 0.4% to $48.82, a 3-month low on 2.0x normal volume
- Closed at $48.82, -0.37% vs the prior close of $49.00. Day range $47.60–$49.54, opened at $48.02.
- Volume was 994.40K shares, 2.0x its 50-day average of 494.28K — unusually heavy trading.
- Price is -20.5% vs its 50-day average ($61.41) and +9.9% vs its 200-day average ($44.41).
- 52-week range $12.94–$72.64; today's close sits at 60% of that range, 32.8% below the 52-week high.
- That makes 7 straight losses.
Oct 13, 2026 — MBX slides 5.8% to $49.00, a 3-month low, 6 down days in a row
- Closed at $49.00, -5.81% vs the prior close of $52.02. Day range $48.91–$53.03, opened at $52.04.
- Volume was 769.00K shares, 1.6x its 50-day average of 486.72K.
- Price is -20.8% vs its 50-day average ($61.85) and +10.6% vs its 200-day average ($44.32).
- 52-week range $12.94–$72.64; today's close sits at 60% of that range, 32.5% below the 52-week high.
- That makes 6 straight losses.
Oct 12, 2026 — MBX dips 2.3% to $52.02, a 3-month low on 2.1x normal volume
- Closed at $52.02, -2.29% vs the prior close of $53.24. Day range $51.89–$54.03, opened at $53.24.
- Volume was 991.60K shares, 2.1x its 50-day average of 478.21K — unusually heavy trading.
- Price is -16.3% vs its 50-day average ($62.16) and +17.6% vs its 200-day average ($44.23).
- 52-week range $12.94–$72.64; today's close sits at 65% of that range, 28.4% below the 52-week high.
- That makes 5 straight losses.
Oct 9, 2026 — MBX ends flat (-0.0%) to $53.24, a 3-month low, 4 down days in a row
- Closed at $53.24, -0.02% vs the prior close of $53.25. Day range $51.88–$53.82, opened at $53.26.
- Volume was 538.80K shares, 1.1x its 50-day average of 478.39K.
- Price is -14.7% vs its 50-day average ($62.44) and +20.6% vs its 200-day average ($44.14).
- 52-week range $12.94–$72.64; today's close sits at 68% of that range, 26.7% below the 52-week high.
- That makes 4 straight losses.
Oct 8, 2026 — MBX dips 2.4% to $53.25, a 3-month low, 3 down days in a row
- Closed at $53.25, -2.37% vs the prior close of $54.54. Day range $50.42–$53.77, opened at $53.66.
- Volume was 413.80K shares, 0.9x its 50-day average of 481.41K.
- Price is -15.1% vs its 50-day average ($62.70) and +20.9% vs its 200-day average ($44.04).
- 52-week range $12.94–$72.64; today's close sits at 68% of that range, 26.7% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — MBX slides 4.2% to $54.54
- Closed at $54.54, -4.18% vs the prior close of $56.92. Day range $53.36–$58.50, opened at $56.38.
- Volume was 357.00K shares, 0.7x its 50-day average of 486.79K.
- Price is -13.3% vs its 50-day average ($62.92) and +24.2% vs its 200-day average ($43.93).
- 52-week range $12.94–$72.64; today's close sits at 70% of that range, 24.9% below the 52-week high.
Oct 6, 2026 — MBX dips 2.8% to $56.92
- Closed at $56.92, -2.77% vs the prior close of $58.54. Day range $55.34–$59.22, opened at $58.75.
- Volume was 366.60K shares, 0.8x its 50-day average of 485.53K.
- Price is -9.7% vs its 50-day average ($63.03) and +30.0% vs its 200-day average ($43.80).
- 52-week range $12.94–$72.64; today's close sits at 74% of that range, 21.6% below the 52-week high.
Oct 5, 2026 — MBX ends flat (+0.1%) to $58.54
- Closed at $58.54, +0.05% vs the prior close of $58.51. Day range $56.42–$59.26, opened at $58.33.
- Volume was 583.20K shares, 1.2x its 50-day average of 483.88K.
- Price is -7.2% vs its 50-day average ($63.11) and +34.1% vs its 200-day average ($43.65).
- 52-week range $12.94–$72.64; today's close sits at 76% of that range, 19.4% below the 52-week high.
Oct 2, 2026 — MBX jumps 3.5% to $58.51
- Closed at $58.51, +3.47% vs the prior close of $56.55. Day range $56.90–$61.12, opened at $59.28.
- Volume was 637.30K shares, 1.3x its 50-day average of 481.89K.
- Price is -7.4% vs its 50-day average ($63.18) and +34.5% vs its 200-day average ($43.50).
- 52-week range $12.94–$72.64; today's close sits at 76% of that range, 19.5% below the 52-week high.
MBX latest news & SEC filings
Every SEC filing by or about MBX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Aug 27, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Aug 17, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 10, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 10, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$37.09M (prior year -$19.41M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.78 (prior year -$0.58) (loss widened vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Azoulay Salomon sold 370 shares at $65.77 (≈$24.33K) on Aug 4, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 4, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 4, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 4, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 4, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 29, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Jul 8, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade MBX
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Mar 12, 2026, Jan 12, 2026. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.92% (largest 7.3%).
- Liquidity: about 591.60K shares (≈$30.00M) trade per day on average.
- 52-week position: $50.71 vs a range of $12.94–$72.64 (63% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 3 open-market buys, 5 sales; latest: Salomon Azoulay sold 370 shares on Aug 4, 2026.
- Latest filings: 8-K Aug 27, 2026; 10-Q Aug 6, 2026; 8-K Aug 6, 2026.
- Share count: 48.16M shares outstanding (Aug 3, 2026), +43.4% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
MBX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 49.15 | 51.30 | 48.73 | 50.71 | 601.80K |
| Oct 14, 2026 | 48.02 | 49.54 | 47.60 | 48.82 | 994.40K |
| Oct 13, 2026 | 52.04 | 53.03 | 48.91 | 49.00 | 769.00K |
| Oct 12, 2026 | 53.24 | 54.03 | 51.89 | 52.02 | 991.60K |
| Oct 9, 2026 | 53.26 | 53.82 | 51.88 | 53.24 | 538.80K |
| Oct 8, 2026 | 53.66 | 53.77 | 50.42 | 53.25 | 413.80K |
| Oct 7, 2026 | 56.38 | 58.50 | 53.36 | 54.54 | 357.00K |
| Oct 6, 2026 | 58.75 | 59.22 | 55.34 | 56.92 | 366.60K |
| Oct 5, 2026 | 58.33 | 59.26 | 56.42 | 58.54 | 583.20K |
| Oct 2, 2026 | 59.28 | 61.12 | 56.90 | 58.51 | 637.30K |
| Oct 1, 2026 | 58.47 | 60.20 | 56.15 | 56.55 | 434.10K |
| Sep 30, 2026 | 58.19 | 59.40 | 56.10 | 58.62 | 523.80K |
| Sep 29, 2026 | 57.27 | 58.24 | 56.55 | 57.75 | 357.10K |
| Sep 28, 2026 | 52.86 | 58.49 | 52.60 | 57.54 | 439.50K |
| Sep 25, 2026 | 55.83 | 56.00 | 52.32 | 53.63 | 563.50K |
| Sep 24, 2026 | 57.56 | 57.72 | 54.41 | 55.39 | 639.00K |
| Sep 23, 2026 | 61.85 | 61.85 | 57.82 | 57.89 | 352.40K |
| Sep 22, 2026 | 61.14 | 63.45 | 60.84 | 61.98 | 433.40K |
| Sep 21, 2026 | 63.46 | 64.61 | 59.97 | 60.94 | 903.30K |
| Sep 18, 2026 | 64.00 | 64.04 | 61.40 | 62.91 | 932.40K |
About MBX Biosciences
MBX Biosciences (MBX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in CARMEL, IN. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1776111.
MBX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Tiba Aynechi | Director | Jun 5, 2026 |
| P. Kent Hawryluk | President & CEO | May 8, 2026 |
| Patrick J Heron | Director | Jun 5, 2026 |
| Steven L. Hoerter | President and CEO | Aug 4, 2026 |
| Edward T Mathers | Director | Jun 5, 2026 |
| Ora H. Pescovitz | Director | Jun 5, 2026 |
| Steven Ryder | Director | Jun 5, 2026 |
| Laurie Stelzer | Director | Jun 5, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Salomon Azoulay | Chief Medical Officer | Aug 5, 2026 |
| Richard Bartram | Chief Financial Officer | Feb 3, 2026 |
| P. Kent Hawryluk | President & CEO | May 8, 2026 |
| Steven L. Hoerter | President and CEO | Aug 4, 2026 |
| John W Smither | Chief Financial Officer | Aug 4, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 4, 2026 | Salomon Azoulay | Sale | 370 | $65.77 |
| May 8, 2026 | Salomon Azoulay | Sale | 55,000 | $38.38 |
| May 8, 2026 | Salomon Azoulay | Sale | 15,003 | $38.30 |
| May 6, 2026 | Salomon Azoulay | Sale | 231 | $29.54 |
| May 6, 2026 | P. Kent Hawryluk | Sale | 607 | $29.54 |
| Mar 13, 2026 | P. Kent Hawryluk | Buy | 18,500 | $28.41 |
| Oct 20, 2025 | P. Kent Hawryluk | Buy | 20,000 | $13.64 |
| Oct 17, 2025 | Steven L. Hoerter | Buy | 20,000 | $13.25 |
MBX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-86.97M | -2.38 | $-79.95M |
| Dec 31, 2024 | — | $-61.92M | -5.82 | $-54.68M |
| Dec 31, 2023 | — | $-32.56M | -31.96 | $-31.98M |
Latest balance sheet: total assets $435.91M, total liabilities $26.37M, cash $54.12M (as of Jun 30, 2026).
MBX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $67.11 |
| May 7, 2026 | 8-K Item 2.02 (results) | $34.71 |
| Mar 12, 2026 | 8-K Item 2.02 (results) | $27.95 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $36.47 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $24.74 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $11.13 |
| May 12, 2025 | 8-K Item 2.02 (results) | $11.14 |
| Mar 17, 2025 | 8-K Item 2.02 (results) | $8.85 |
| Jan 7, 2025 | 8-K Item 2.02 (results) | $14.60 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $23.22 |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on MBX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.